195 related articles for article (PubMed ID: 25340858)
21. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
22. DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.
Wang J; Sun L; Yang M; Luo W; Gao Y; Liu Z; Qiu X; Wang E
J Histochem Cytochem; 2013 Jul; 61(7):510-21. PubMed ID: 23571382
[TBL] [Abstract][Full Text] [Related]
23. [Construction of RNA interference (RNAi) lentiviral expression vector of DEK gene and its effect on the biological behavior of liver cancer cells].
Li SH; Hou Y; Chen Z; Wu WR; Wu CX; Sun H
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):868-875. PubMed ID: 33105933
[No Abstract] [Full Text] [Related]
24. DEK modulates both expression and alternative splicing of cancer‑related genes.
Liu B; Sun Y; Zhang Y; Xing Y; Suo J
Oncol Rep; 2022 Jun; 47(6):. PubMed ID: 35475534
[TBL] [Abstract][Full Text] [Related]
25. Long noncoding RNA SOX2OT maintains the stemness of pancreatic cancer cells by regulating DEK via interacting with miR-200a/141.
Liu CS; Zhou Q; Zhang YD; Fu Y
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2368-2379. PubMed ID: 32196588
[TBL] [Abstract][Full Text] [Related]
26. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI
Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316
[TBL] [Abstract][Full Text] [Related]
27. Intercellular trafficking of the nuclear oncoprotein DEK.
Saha AK; Kappes F; Mundade A; Deutzmann A; Rosmarin DM; Legendre M; Chatain N; Al-Obaidi Z; Adams BS; Ploegh HL; Ferrando-May E; Mor-Vaknin N; Markovitz DM
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6847-52. PubMed ID: 23569252
[TBL] [Abstract][Full Text] [Related]
28. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
29. High expression of DEK is associated with poor prognosis in hepatocellular carcinoma.
Lee SY; Jung W; Lee J; Kim A; Kim HK; Kim BH
Histol Histopathol; 2019 Nov; 34(11):1279-1288. PubMed ID: 31066459
[TBL] [Abstract][Full Text] [Related]
30. DEK overexpression is correlated with the clinical features of breast cancer.
Liu S; Wang X; Sun F; Kong J; Li Z; Lin Z
Pathol Int; 2012 Mar; 62(3):176-81. PubMed ID: 22360505
[TBL] [Abstract][Full Text] [Related]
31. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.
Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A
Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-138 promotes neuroblastoma SH-SY5Y cell apoptosis by directly targeting DEK in Alzheimer's disease cell model.
Miao J; Jing J; Shao Y; Sun H
BMC Neurosci; 2020 Jul; 21(1):33. PubMed ID: 32736520
[TBL] [Abstract][Full Text] [Related]
33. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
[TBL] [Abstract][Full Text] [Related]
34. The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma.
Palazzo JP; Kafka NJ; Grasso L; Chakrani F; Hanau C; Cuesta KH; Mercer WE
Hum Pathol; 1997 Oct; 28(10):1189-95. PubMed ID: 9343326
[TBL] [Abstract][Full Text] [Related]
35. SiRNA knockdown of the DEK nuclear protein mRNA enhances apoptosis and chemosensitivity of canine transitional cell carcinoma cells.
Yamazaki H; Iwano T; Otsuka S; Kagawa Y; Hoshino Y; Hosoya K; Okumura M; Takagi S
Vet J; 2015 Apr; 204(1):60-5. PubMed ID: 25773167
[TBL] [Abstract][Full Text] [Related]
36. DEK over-expression promotes mitotic defects and micronucleus formation.
Matrka MC; Hennigan RF; Kappes F; DeLay ML; Lambert PF; Aronow BJ; Wells SI
Cell Cycle; 2015; 14(24):3939-53. PubMed ID: 25945971
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis.
Matrka MC; Watanabe M; Muraleedharan R; Lambert PF; Lane AN; Romick-Rosendale LE; Wells SI
PLoS One; 2017; 12(5):e0177952. PubMed ID: 28558019
[TBL] [Abstract][Full Text] [Related]
38. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
[TBL] [Abstract][Full Text] [Related]
39. The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.
Sandén C; Järvstråt L; Lennartsson A; Brattås PL; Nilsson B; Gullberg U
Mol Cancer; 2014 Sep; 13():215. PubMed ID: 25216995
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway.
Du W; Hong J; Wang YC; Zhang YJ; Wang P; Su WY; Lin YW; Lu R; Zou WP; Xiong H; Fang JY
J Cell Mol Med; 2012 Aug; 16(8):1878-88. PubMed ID: 22050790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
